TrendSetter67
Posted - 04/25/24
$VXRT $HLVX 👀👀👀
TrendSetter67
Posted - 04/18/24
$VXRT Moderna is flooding the field with trials in many diseases and promoting early positive results given their COVID revenue has dried up - fast. The Ph1 trials had 2 candidates with ~60 per cohort ; a Tri and Penta-Valent version. They are all quiet on Penta results and only showing HGBA data for the Tri version. Hmmm.
For Norovirus, $HLVX as an injectable, has much more to worry than Vaxart's pill. We will always be competing with jabs and mRNA entry into Noro does not negate but rather further emphasizes the differentiator of being both a mucosal vaccine and a tablet with all its added benefits, which is especially attractive to WHO and GAVI to provide price and access equity to lesser nations.
Hillevax, like other non-revenue bios, continues to chart stumble as well as has major trial design delays last year. With Noro, Hillevax are at extreme risk vs mRNA to become another jab VLP like Novavax which gets trampled by a mRNA jab comparable.
TrendSetter67
Posted - 04/16/24
$VXRT $HLVX ready to break a support level and trade below major moving averages.
Night_Owl_Biotech
Posted - 04/14/24
We track the share prices of 12 biopharmas that are primarily focused on vaccine therapies. The attachment notes the share prices of the subject 12 since year end. We are only aware of Iscovax that was recently acquired. 11 of the 12 are trading lower year to date. Please let us know if we are missing any biopharmas primarily, again primarily, focused on developing vaccine therapies. We are aware of those with vaccines in their portfolio like AGEN. As always, our data could be wrong. Thank you. $HLVX $PCVX $DVAX $ARCT $NVAX
TrendSetter67
Posted - 04/10/24
$VXRT It appears those insiders been trying to get ahead of the chart collapse ongoing in $HLVX with their selling the past 5 months.
TrendSetter67
Posted - 04/09/24
$VXRT Meanwhile, while $HLVX insiders have activated individual free market exit strategies, we must be giving out too generous incentive shares as insiders continue to be disinterested in purchaser independent shares down here at $1, even as a confidence statement.
TrendSetter67
Posted - 04/09/24
$VXRT Someone will have some hard convincing that $HLVX is seeing good Phase 2 data in their Noro trials as CFO, CMO and CBO all been dumping shares hard the last 5 months. Wow! 🤮🤮🤮
http://insiderbuyingselling.com/?t=HLVX
insiderbuyingselling
Posted - 04/09/24
$HLVX new insider buying: 8850 shares. http://insiderbuyingselling.com/?t=HLVX
insiderbuyingselling
Posted - 04/05/24
$HLVX new insider selling: 18000 shares. http://insiderbuyingselling.com/?t=HLVX
StockInvest_us
Posted - 03/29/24
Signal alert: $HLVX - Oversold Trend Short (Undervalued) https://stockinvest.us/l/o1ZCjF59ig
DailyStocksPicks
Posted - 03/27/24
My Oversold pick #2 for today is $CABA This company is working on developing targeted cell therapies for autoimmune diseases. With FDA designations advancing its clinical trials and a solid financial strategy aimed at supporting its pipeline, analysts also see significant growth potential despite its current financial losses. $EXAI, $ALLO, $TRML, $HLVX https://youtu.be/7pOcCYEQIxM
DailyStocksPicks
Posted - 03/26/24
Today's Oversold Stock #4: Cabaletta Bio ($CABA): Despite a recent stock price drop and an earnings miss, the company has achieved FDA Orphan Drug Designation for one of its treatments and shows promising progress in clinical trials. This suggests the stock might be oversold, with the market not fully recognizing Cabaletta Bio's potential in the biotech industry. $HLVX, $PRME, $TRML, $ALLO For More Details: https://youtu.be/JXc_UbBbj1o
Fullratio
Posted - 03/23/24
$HLVX total liabilities has soared by 58% YoY and by 15% from the previous quarter: https://fullratio.com/stocks/nasdaq-hlvx/hillevax
DailyStocksPicks
Posted - 03/22/24
Today's Oversold Stock #4: Cabaletta Bio ($CABA): Despite a recent stock price drop and an earnings miss, the company has achieved FDA Orphan Drug Designation for one of its treatments and shows promising progress in clinical trials. This suggests the stock might be oversold, with the market not fully recognizing Cabaletta Bio's potential in the biotech industry. $HLVX, $PRME, $TRML, $ALLO For Detailed https://youtu.be/kiXj5yPn9rc
insiderbuyingselling
Posted - 03/20/24
$HLVX new insider selling: 18000 shares. http://insiderbuyingselling.com/?t=HLVX
DonCorleone77
Posted - 03/20/24
$HLVX HilleVax files $500M mixed securities shelf
DonCorleone77
Posted - 03/20/24
$HLVX HilleVax reports Q4 EPS (78c), consensus (83c) As of December 31, 2023 and December 31, 2022, the company had cash, cash equivalents and marketable securities totaling $303.5M and $279.4M, respectively. The increase was due to $107.8M of net proceeds received from the issuance of common stock in an underwritten public offering. "Over the past year, we made significant progress with HIL-214, our vaccine candidate for the prevention of moderate-to-severe norovirus related acute gastroenteritis. We have continued to progress the NEST-IN1 clinical trial and remain on track to report topline data by mid-2024," said Rob Hershberg, chairman and CEO of HilleVax. "We have also made good progress on our manufacturing activities for HIL-214 in support of continued development in subsequent registrational trials for infants and older adults."
Stock_Titan
Posted - 03/20/24
$HLVX HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company Progress
https://www.stocktitan.net/news/HLVX/hille-vax-reports-full-year-2023-financial-results-and-highlights-nzb19axwwfjr.html
TrendSetter67
Posted - 03/20/24
$VXRT I wonder why $HLVX is buying a new VLP construct (China) to a wider Noro strain set. They are late into multiple Phase 2 trials for infant and adult on their bivalent vaccine. Are they seeing problems with cross reactivity? 🧐🧐🧐. What is their current IP worth if they are licensing a broader vaccine from China?
Their pps been sliding hard since hitting $20
DailyStocksPicks
Posted - 03/20/24
Today's Oversold Stock #4: Cabaletta Bio ($CABA): Cabaletta Bio stands at the crossroads of volatility and opportunity. As it navigates through earnings reports and healthcare conferences, what does the influx of institutional investments signify for its future? Delve into the dynamics affecting $CABA's stock and why it might be seen as oversold. Discover the factors influencing investor sentiment and market trends in our comprehensive review. $HLVX, $PRME, $TRML, $ALLO For Detailed $CABA Analysis Watch: https://youtu.be/Rp7HXX5q-1I
DailyStocksPicks
Posted - 03/19/24
Cabaletta Bio ($CABA): Factors such as volatility, upcoming earnings, and participation in health care conferences have led to perceptions of the stock being oversold. Institutional investments and analyst ratings suggest optimism, but the volatility inherent in the biotech sector and speculative trading ahead of key announcements have contributed to this sentiment. $HLVX, $PRME, $TRML, $ALLO For Detailed $CABA Analysis Watch: https://youtu.be/_2AzeWeByGY
insiderbuyingselling
Posted - 03/09/24
$HLVX new insider selling: 18000 shares. http://insiderbuyingselling.com/?t=HLVX
TrendSetter67
Posted - 2 months ago
$VXRT $HLVX nearing $1 billion n market cap for a Noro vaccine that is inferior to Vaxart's pill. Come on Tucker ... get us those CoPs and let's get the Phase 2b/3 trials on the schedule.
Doozio
Posted - 02/24/24
$HLVX so NICE has to mention it twice! 🧠⏰♾️ whUt about FOUR?
Doozio
Posted - 02/24/24
$HLVX chop chop huckleberries 🧠⏰
insiderbuyingselling
Posted - 02/13/24
$HLVX new insider selling: 11597 shares. http://insiderbuyingselling.com/?t=HLVX
insiderbuyingselling
Posted - 02/12/24
$HLVX new insider selling: 3576 shares. http://insiderbuyingselling.com/?t=HLVX
Stock_Titan
Posted - 02/05/24
$HLVX HilleVax to Present at Guggenheim 6th Annual Biotechnology Conference
https://www.stocktitan.net/news/HLVX/hille-vax-to-present-at-guggenheim-6th-annual-biotechnology-t25zeql2b4ox.html
cctranscripts
Posted - 01/22/24
Report of proposed sale of securities https://www.conferencecalltranscripts.org/summary/?id=12884201 $HLVX
